REGISTER RECORD · ctis
2023-503444-13-00
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | The register records no status for this entry. |
|---|---|
| Register last updated | 2026-09-28 |
| Retrieved by this site | 2026-10-03 |
| Source | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-503444-13-00 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.